AUTOIMMUNE DISEASE THERAPEUTICS - A GLOBAL STRATEGIC BUSINESS REPORT   

Research Abstract

This report analyzes the worldwide markets for Autoimmune Disease Therapeutics in US$ Million by the following Therapeutic Class: Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn's Disease (Biologics), and Others. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain. The report profiles 138 companies including many key and niche players such as -

Abbott Laboratories
Amgen Inc.
Bayer Schering Pharma AG
Biogen Idec Inc.
Bristol-Myers Squibb Company
Elan Corporation Plc


Click here to request a full list of companies covered in the report...

Code: MCP-1829
Price: $4500
Companies: 138
Pages: 877
Date: October 2011
Market Data Tables: 219

Complimentary Market Brief:


Request a Complimentary Copy of the Report Insights, Key Findings, Drivers, Trends, Program Sources, and Methodology.
Salutation:
First Name:
Last Name:
Email ID: (Domain Specific Email Required)
Company:
NOTE: Generic Email IDs such as AOL, Hotmail, Yahoo, Gmail, MSN etc. cannot be used

 TABLE OF CONTENTS


 
   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Quantitative Techniques & Analytics.....I-3
Product Definition and Scope of Study.....I-3
Rheumatoid Arthritis.....I-3
  
   Multiple Sclerosis.....I-4
Psoriasis.....I-4
Crohn's disease.....I-4
  
   Autoimmune Disease Therapeutics Market Continues to Flourish.....II-5
Pharmaceutical Industry Hit by Economic Downturn.....II-5
1$100
   Economic Downturn Takes Toll on R&D.....II-6
Current and Future Analysis.....II-6
Segment Analysis.....II-6
1$100
   Rheumatoid Arthritis Therapeutics – The Largest Segment.....II-7
Multiple Sclerosis Therapeutics Market.....II-7
Crohn’s Disease Therapeutics Market.....II-7
1$100
   Ulcerative Colitis Drugs Market.....II-81$100
   Biologics Find Acceptance as First Line of Treatment for Autoimmune Diseases.....II-9
High Unmet Need Favors Growth.....II-9
Impact of Biosimilars Legislation on Biologic Arthritis Drugs Market.....II-9
1$100
   New Products to Drive Market Growth.....II-10
Biogenerics to Expand Adoption of Biological Drugs.....II-10
Risk of Cancer Due to Anti-TNF Drugs.....II-10
1$100
   Superior Outcomes to Enhance Adoption of Biologics.....II-11
Efficacy and Convenience – Key Factors Driving Physician’s Decision.....II-11
1$100
   Immunity and Immune System.....II-12
Autoimmune Diseases.....II-12
Women- Highly Susceptible to Autoimmune Diseases.....II-12
1$100
   Table 1: Percentage Breakdown of Incidence of Autoimmune Diseases in Men and Women (includes corresponding Graph/Chart).....II-131$350
   Complexity in Manifestations Renders Difficulty in Understanding the
  Conditions.....II-14
Etiology of Autoimmune Diseases.....II-14
Genetic Predisposition.....II-14
1$100
   Environmental Factors.....II-15
Autoimmune Diseases – A Social and Health Burden.....II-15
Regulatory Glitches and High Costs Hinder Biogenerics.....II-15
1$100
   Types of Autoimmune Diseases.....II-16
Incidence and Prevalence.....II-16
1$100
   Diagnosis and Treatment of Autoimmune Diseases.....II-17
Overview on Select Biologic Drugs.....II-17
Remicade.....II-17
1$100
   Humira.....II-18
Rituxan® (rituximab).....II-18
Cimzia.....II-18
1$100
   Cimzia to Face Stiff Competition in Rheumatoid Arthritis Market.....II-19
Psoriasis – A Promising Market for Cimzia.....II-19
1$100
   Actemra.....II-20
Enbrel.....II-20
1$100
   Rheumatoid Arthritis.....II-21
Disease Overview.....II-21
Low Penetration to Sustain growth of Anti-TNF Drugs.....II-21
Incidence and Prevalence Higher in Urban and Developed Regions.....II-21
1$100
   Symptoms and Diagnosis.....II-22
Treatment of Rheumatoid Arthritis.....II-22
BRMs Revolutionize RA Treatment.....II-22
Branded Products.....II-22
1$100
   Drugs Used in Treating Rheumatoid Arthritis.....II-23
Year of Approval of Leading Biologics in Rheumatoid Arthritis Therapy.....II-23
Key Drugs in Late Stage Development for Rheumatoid Arthritis Treatment.....II-23
1$100
   Competitive Landscape.....II-24
Table 2: Comparative Analysis of Leading Biologic Rheumatoid Arthritis Drugs based on ACR Scores by End Point.....II-24
1$350
   High Prices and Safety Concerns.....II-25
Multiple Sclerosis.....II-25
Etiology.....II-25
1$100
   Types of Multiple Sclerosis.....II-26
Table 3: Prevalence of Different Types of Multiple Sclerosis.....II-26
Pathology.....II-26
1$350
   Prevalence of Multiple Sclerosis High in Women.....II-27
Facts About Multiple Sclerosis.....II-27
Treatment.....II-27
1$100
   Interferon Drugs - High Efficacy Drugs in Existing MS Therapies.....II-28
Beta Interferon Drugs in Multiple Sclerosis Treatment.....II-28
Non-Interferon Drugs.....II-28
1$100
   Non-Interferon Drugs in Multiple Sclerosis Treatment.....II-29
Trends in Multiple Sclerosis Market.....II-29
High Unmet Need and Rich Pipeline to Expand MS Market.....II-29
Interferon-based Drugs Lead Multiple Sclerosis Drug Market.....II-29
1$100
   Oral Drugs Alter Dynamics in MS Therapies Market.....II-30
Dip in Sales Inevitable for Current Therapies.....II-30
1$100
   Tough Times Ahead for Betaseron.....II-31
Competitive Landscape.....II-31
1$100
   Table 4: Leading Products/Companies in the Global Multiple Sclerosis Therapeutics Market (2010): Percentage Share Breakdown of Value Sales for Biogen Idec, Teva/sanofi-aventis, Merck Serono, Bayer Schering, Elan, and Others (includes corresponding Graph/Chart).....II-321$350
   Multiple Sclerosis Drug Pipeline – An Overview.....II-33
Drugs Under Development for Treating Multiple Sclerosis.....II-33
Fingolimod (Gilenya).....II-33
Mylinax.....II-33
1$100
   Laquinimod.....II-34
Campath (Alemtuzumab).....II-34
1$100
   Teriflunomide.....II-35
Fampridine-SR.....II-35
BG-12 (Oral Fumarate).....II-35
MN-166.....II-35
1$100
   Psoriasis.....II-36
Prevalence.....II-36
Available Treatment Options.....II-36
1$100
   Biological Drugs.....II-371$100
   Biological Drugs Lead the Fray.....II-38
Potential Therapeutic Products.....II-38
Inflammatory Bowel Diseases.....II-38
Crohn's disease.....II-38
1$100
   Stages of the Disease.....II-39
Prevalence.....II-39
Diagnosis.....II-39
Treatment.....II-39
2$200
   Ulcerative Colitis.....II-41
Diagnosis and Treatment.....II-41
Other Diseases.....II-41
Systemic Lupus Erythematosus (SLE).....II-41
1$100
   Prevalence and Epidemiology.....II-42
Treatment.....II-42
Sjogren's Syndrome.....II-42
1$100
   Prevalence and Epidemiology.....II-43
Diagnosis and Treatment.....II-43
1$100
   Type-1 Diabetes Mellitus.....II-44
Types of Diabetes Mellitus.....II-44
Type 1 or Insulin Dependent Diabetes Mellitus.....II-44
Type 2 or Non-Insulin Dependent Diabetes Mellitus.....II-44
Insulin – Vital for Blood Glucose Management.....II-44
1$100
   Etiology.....II-45
Prevalence.....II-45
Diabetes in Children - A Growing Concern.....II-45
Diagnosis and Treatment.....II-45
1$100
   Autoimmune Hepatitis.....II-46
Disease Categories.....II-46
Treatment.....II-46
Side Effects.....II-46
1$100
   Juvenile Rheumatoid Arthritis.....II-47
Symptoms.....II-47
Diagnosis.....II-47
Scleroderma.....II-47
1$100
   Prevalence.....II-48
Etiology.....II-48
Diagnosis.....II-48
Management.....II-48
Vasculitis Syndeomes.....II-48
1$100
   Haematologic Autoimmune Diseases.....II-49
Ankylosing Spondylitis.....II-49
1$100
   Antares Pharma Commences VIBEX MTX Clinical Trial for Treating Rheumatoid
  Arthritis.....II-50
Avila Therapeutics Introduces Btk Inhibitor for Treating Autoimmune Diseases and
  Cancer.....II-50
Athersys and Angiotech to Conduct MultiStem® Clinical Trial.....II-50
1$100
   BioMarin Commences Amifampridine Phosphate Clinical Trial for Treating LEMS.....II-51
TxCell Successfully Completes Trial for Crohn's Disease Cell Therapy.....II-51
Novartis Releases Phase II Data for AIN457.....II-51
Sanofi Releases Phase III TEMSO Study Results of Teriflunomide.....II-51
1$100
   Biogen Achieves Positive Results for BG-12 Drug Trial.....II-52
Innate Therapeutics Commences MIS416 Clinical Trial in Progressive MS Patients.....II-52
Pfizer Completes Clinical Trials for Tasocitinib.....II-52
1$100
   Compugen Completes Animal Model Study of CGEN-15001.....II-53
Avila Therapeutics Commences AVL-292 Clinical Trial.....II-53
1$100
   Horizon Pharma Completes Clinical Trials for LODOTRA®.....II-54
ChemoCentryx Begins Phase 1 Clinical trial for CCX168.....II-54
NYU Langone Medical Center Announces Potential Therapy for Rheumatoid
  Arthritis.....II-54
1$100
   Compugen to Start Preclinical Development for Therapeutic Drugs.....II-55
Avila Therapeutics Begins Phase I Clinical Trial for AVL-292.....II-55
1$100
   VBL Therapeutics Releases Preclinical Data for VB-201.....II-56
GlaxoSmithKline and Dynavax Select DV1179 for Endosomal TLR Inhibitor Program.....II-56
1$100
   Idera Pharmaceuticals Starts Phase 1 Clinical Study of IMO-3100.....II-571$100
   ChemoCentryx Begins Phase I Clinical Study of CCX168.....II-58
VBL Therapeutics Starts Phase II Clinical Study of VB-201.....II-58
1$100
   ChemoCentryx Begins Phase II Clinical Study of CCX354.....II-59
Neovacs Starts Phase IIa Clinical Study of TNF Kinoid.....II-59
1$100
   Galapagos Begins Phase II Clinical Study of Nanocort.....II-60
Plexxikon Starts Dosing of PLX3397 in Phase I Clinical Study.....II-60
2$200
   Horizon Pharma Receives FDA Approval for DUEXIS®.....II-62
Venus Remedies to Launch Trois.....II-62
CNRS/Inserm Researchers Introduce Dendrimer ABP as RA Therapy.....II-62
1$100
   Food and Drug Monitoring Agency to Approve Tocilizumab for Commercial Use.....II-63
Novartis Bags EC Approval for Gilenya®.....II-63
Genentech Obtains FDA Approval for ACTEMRA.....II-63
Novartis Gains Approval for Gilenya in Japan.....II-63
1$100
   Novartis Receives FDA Approval for Gilenya.....II-64
Compugen Discovers and Validates CGEN-15001 Soluble Recombinant Fusion Protein.....II-64
InNexus Biotechnology Develops IXSCD11a.....II-64
Centocor Ortho Biotech Submits sBLA for Simponi Label Extension.....II-64
1$100
   Osiris Therapeutics Obtains Orphan Drug Designation for Prochymal from FDA.....II-65
Immunomedics Obtains US Patent for Immunotherapy.....II-65
Biogen Idec Introduces Monoclonal Antibody Tysabri in India.....II-65
1$100
   Merck Serono Unveils Pre-Filled Pen RebiDose™ in UK .....II-66
BioMarin Unveils Firdapse™ in European Union.....II-66
Sandoz Introduces Calcipotriene Solution in US.....II-66
Cimzia® Receives FDA Approval for Treating Rheumatoid Arthritis.....II-66
1$100
   Simponi™ Receives FDA Approval for Treating Rheumatoid Arthritis.....II-67
Novartis Introduces Extavia® for Multiple Sclerosis Treatment in Denmark &
  Germany.....II-67
Novartis Bags FDA Approval for Extavia.....II-67
UCB Receives EC Approval for Cimzia.....II-67
1$100
   Centocor Ortho Biotech Receives FDA Approval for Stelara.....II-68
BioMarin Pharmaceutical Bags FDA’s Orphan Drug Designation.....II-68
Promius Pharma Introduces Scytera™ for Psoriasis Treatment.....II-68
Galderma Receives FDA Approval for Plaque Psoriasis Ointment Vectical™.....II-68
Roche Obtains EC Approval for Rheumatoid Arthritis Antibody RoACTEMRA.....II-68
1$100
   Viron Therapeutics Obtains US Patents for VT-384, VT-346 Candidates.....II-69
Bayer Schering Pharma Obtains Approval for Betafron® Therapy from SFDA.....II-69
US Food and Drug Administration Approves Certolizumab Pegol.....II-69
Nitec Unveils Lodotra® in Germany.....II-69
1$100
   HUMIRA® Obtains EU Approval for Polyarticular Juvenile Idiopathic Arthritis.....II-70
Cimzia® Receives FDA Nod for Treating Crohn’s Disease.....II-70
HUMIRA® Obtains Approval from Japanese Ministry for Rheumatoid Arthritis.....II-70
HUMIRA® Receives FDA Clerance for Polyarticular Juvenile Idiopathic Arthritis.....II-70
1$100
   Abbott Receives EU Marketing Authorization for Humira in Psoriasis Treatment.....II-71
Xian-Janssen Introduces Remicade, Branded infliximab in China.....II-71
HUMIRA® Obtains EU Approval for Treating Crohn’s Disease.....II-71
HUMIRA® Obtains FDA Approval for Crohn’s Disease.....II-71
Remicade® Obtains Approval for Use in PsA and Early RA in Australia.....II-71
1$100
   Tysabri™ Receives Health Canada Approval for Use in Multiple Sclerosis.....II-72
Rituxan® Gets FDA Approval for Use in RA.....II-72
1$100
   Humira® Obtains FDA Approval for Treating AS.....II-73
Betaseron® Receives FDA Approval for Use in First Clinical Episode of MS.....II-73
Abbott Receives FDA Clearance for HUMIRA Pen.....II-73
1$100
   Remicade Obtains FDA Approval for Treating Pediatric Crohn`s Disease.....II-741$100
   Sanofi-Aventis Takes over Genzyme.....II-75
Daiichi Sankyo to Acquire Plexxikon.....II-75
TiGenix Takes Over Cellerix.....II-75
Alkermes and Elan Drug Technologies to Merge Operations.....II-75
1$100
   Pfizer Japan Inks Agreements with Takeda to Co-Promote RA Drugs.....II-76
Viropro Inks Letter of Agreement with Spectrum Pharmaceuticals.....II-76
Pepscan Therapeutics Collaborates with Phylogica.....II-76
1$100
   Lycera Enters into Research Collaboration with Merck.....II-77
Merck Amends Distribution Agreement with Johnson & Johnson.....II-77
Yale University and Debiopharm Enter into License Agreement for Debio 1036.....II-77
Opexa Therapeutics Inks Agreement with American Red Cross.....II-77
1$100
   Antitope and NasVax Enter into Research Collaboration.....II-78
SuppreMol Inks In-License Agreement with Bayerische Patentallianz.....II-78
Glenmark Inks License Agreement with Sanofi.....II-78
1$100
   Exagen Enters into Partnership with Medco.....II-79
Phylogica Inks Research Collaboration and Option Agreement with Pepscan
  Therapeutics.....II-79
Merck Sharp & Dohme Enters into Partnership with Lycera.....II-79
1$100
   Amgen Enters into Collaboration with Xencor.....II-80
PhRMA Announces Development of Medicines Targeted Towards Women.....II-80
1$100
   Circassia Secures Global Development and Marketing Rights to PAP-1 from Airmid.....II-81
UCB Establishes Microbial Production Facility.....II-81
Emergent BioSolutions Takes Over Trubion Pharmaceuticals.....II-81
Gilead Sciences to Takeover CGI Pharmaceuticals.....II-81
1$100
   Abbott Laboratories Acquires Facet Biotech.....II-82
Merck Takes Over Millipore.....II-82
Quidel to Snap Up Diagnostic Hybrids.....II-82
1$100
   Nitec Pharma Merges with Horizon Therapeutics.....II-83
Femta Pharmaceuticals Inks Manufacturing Agreement with Lonza Group.....II-83
Horizon Pharma Signs Agreement with Mundipharma International.....II-83
3SBio Signs Agreement with Isotechnika Pharma.....II-83
1$100
   Fast Forward and Provid Pharmaceuticals Extend Partnership.....II-84
Antitope and PIKAMAB Collaborate.....II-84
Ligon Discovery Enters into Agreement with Lycera.....II-84
1$100
   Axxam, Fast Forward and Juvenile Diabetes Research Foundation Enter into
  Partnership.....II-85
GlaxoSmithKline Collaborates with ChemoCentryx.....II-85
Perseid Signs Agreement with Astellas Pharma for CTLA4-Ig Program.....II-85
Cellceutix Chooses Destum Partners for KM-133 Psoriasis Compound.....II-85
1$100
   NERC Commences Operations of IXO Therapeutics.....II-86
Avesthagen to Market Avent.....II-86
Isotechnika Pharma Divests Stake in Isodiagnostika.....II-86
1$100
   MacroGenics Obtains New Grants from NIH.....II-87
AnaptysBio Collaborates with VLST to Generate Novel Antibody Therapeutics.....II-87
AstraZeneca Enters into Exclusive License Agreement with Rigel Pharmaceuticals.....II-87
Immutep Inks License Agreement with GlaxoSmithKline for Therapeutic Antibody
  IMP731.....II-87
1$100
   Novo Nordisk Inks Research Collaboration Agreement with Combine.....II-88
Xention and Axxam Enter into Autoimmune Disorder Research Partnership.....II-88
Roche Takes Over Genentech.....II-88
Merck Acquires Schering-Plough.....II-88
1$100
   Pfizer Takes Over Wyeth.....II-89
Amgen Takes Over Immunex.....II-89
BioMarin Pharmaceutical Takes Over Huxley Pharmaceuticals.....II-89
Onyx to Takeover Proteolix.....II-89
Genzyme Takes Over Global Rights of Campath, Leukine and Fludara from Bayer.....II-89
1$100
   Bristol-Myers Squibb Enters into Agreement with Alder Biopharmaceuticals.....II-90
LEO Pharma Inks Agreement with Warner Chilcott.....II-90
Kineta One Acquires Commercial Rights for Compounds from Airmid.....II-90
1$100
   Kineta Signs Agreement with Alturas Analytics.....II-91
Catalyst Biosciences in Research and License Agreement with MedImmune.....II-91
Boehringer Ingelheimes Collaborates with Exelixis.....II-91
Lonza Signs Agreement with Opsona Therapeutics for Manufacturing Antibody.....II-91
1$100
   Eli Lilly and Incyte Enter into Agreement.....II-92
Novartis Option Fund and Avila Therapeutics Sign Option Agreement.....II-92
Genentech Acquires Rights for BHT-3021 from Bayhill Therapeutics.....II-92
Celentyx and Meiji Seika Kaisha Ink Agreement.....II-92
1$100
   Exelixis and Boehringer Ingelheim Enter into Autoimmune Disease Partnership.....II-93
Celldex Acquires Exclusive Rights of Immune-Stimulatory Molecules from Amgen.....II-93
Apitope and Merck Serono Sign Agreement for Multiple Sclerosis Drug.....II-93
Biovitrum and Affibody® Enter into Collaboration.....II-93
1$100
   Bayhill Therapeutics Bags Contract from Genentech.....II-941$100
   Novo Nordisk and VLST Collaborate on Therapeutic Targets Development.....II-95
Actemra’s Approval Gets Delayed.....II-95
1$100
   Apitope Raises Financing for Developing Multiple Sclerosis Compound.....II-96
CalciMedica to Acquire Rights to STIM1 from TorreyPines.....II-96
1$100
   Roche Acquires ARIUS Research, Inc......II-97
Astellas Inks Agreement with Maxygen for MAXY-4 Candidates.....II-97
1$100
   Carna and Caliper Life Sciences Ink Collaborative Supply Agreement.....II-98
Isotechnika Gets Back Worldwide Rights to Transplant Drug, Voclosporin.....II-98
Boehringer In-licenses Two Drug Targets from BioFocus.....II-98
1$100
   Bionomics Enters into a Development and Licensing Agreement with Merck Serono.....II-99
Nycomed Inks Agreement with Immunomedics for Veltuzumab.....II-99
1$100
   EpiVax Receives Grants from National Institutes of Health to Advance Epi-13.....II-100
Boehringer to Takeover Actimis.....II-100
1$100
   Antisoma Acquires Xanthus Pharmaceuticals.....II-101
Merrimack Acquires Funds for Developing Cancer and Autoimmune Disease
  Biologics.....II-101
BioSeek and Merck Sign Collaboration Agreement for Compound Evaluation.....II-101
1$100
   Questcor Amends Distribution Contract with US Distributor of Acthar.....II-102
ANP Completes Phase IIa Trial for Multiple Sclerosis Drug.....II-102
Insert and Calando Merge to Form Calando Pharmaceuticals.....II-102
1$100
   Codon Inks Research & Development and Licensing Deal with Merrimack.....II-103
Debiopharm Inks licensing Deal with Airmid for Debio 0824 ShK Peptide.....II-103
Chelsea Acquires Global Rights to I-3D Range of DHODH Inhibiting Compounds.....II-103
1$100
   Cypress Bioscience Acquires Proprius.....II-104
J&J PRD Grants Milestone Payment to Sunesis Pharmaceuticals.....II-104
1$100
   GlaxoSmithKline Acquires License to Market Vaccinex’s Antibody.....II-105
Teva to Takeover CoGenesys.....II-105
Hadasit, HMS and BWH to Co-develop Oral Therapy for Autoimmune Diseases.....II-105
Anthera Acquires Rights to Develop and Market AMG 623 from Amgen.....II-105
Can-Fite Enters into Two Cooperation Agreements to Develop CF102 Drug.....II-105
1$100
   Source MDx Inks an Agreement with Pfizer.....II-106
Cambridge Inks an Antibody Development Agreement with Medarex.....II-106
1$100
   Pfizer to Acquire Coley Pharma.....II-107
GSK Joins Hands with Tolerx to Develop and Commercialize otelixizumab.....II-107
1$100
   Amgen Acquires Avidia.....II-108
Eli Lilly and MacroGenics Tie Up for Developing Teplizumab.....II-108
1$100
   MorphoSys and Genesis Ink Antibody R&D Deal.....II-109
arGentis Enters into a License Agreement with UTRF.....II-109
Eden Biodesign to Investigate Novel Drug Candidate for Autoimmune Diseases.....II-109
1$100
   Nuon and Kissei Team up for Tranilast.....II-110
Organon and Dyax Team Up for Developing Therapeutic Antibodies.....II-110
Medarex Joins Hands with Mitsubishi for Monoclonal Antibody Development.....II-110
Merck and Archemix Collaborate.....II-110
1$100
   Genzyme Takes Over Bioenvision.....II-111
Organon and Medarex Ink Drug Development Deal.....II-111
CalciMedica Secures Exclusive Rights for CBR’s Autoimmune Drug Target.....II-111
1$100
   Xanthus Secures Exclusive Patent Estate Rights for FLT3 Pathway.....II-112
Eisai Corporation Acquires Morphotek.....II-112
TIRC Changes Name to Orchestra Therapeutics.....II-112
1$100
   Abbott Files HUMIRA® for Psoriasis in the US and EU (USA/Europe).....II-113
Accentia Secures Exclusive Global Rights to Revimmune.....II-113
1$100
   Medarex and Compugen Ink Collaborative Agreement for Therapeutic Antibody.....II-114
SRI and Telik Sign License Agreement for Drug Development.....II-114
1$100
   China Biopharma Signs Agreement with Chinese Biopharmaceutical Firm.....II-1151$100
   Kirin and Astellas Ink Licensing Agreement for Anti-CD40 Antagonistic mAb.....II-116
QSV and Artielle Sign Contract to Produce RTL-1000.....II-116
JDRF and MacroGenics Form Partnership.....II-116
1$100
   GSK and Genmad Sign Partnership Agreement for HuMaxCD20.....II-117
Biocon Enters into Joint Venture Agreement with Neopharma.....II-117
1$100
   Pipex Pharmaceuticals Acquires Remaining Stake in Effective Pharmaceuticals.....II-118
Astellas Acquires Worldwide Rights for Amevive®.....II-118
1$100
   Biogen Acquires Fumapharm.....II-119
Biogen and UCB Join Hands for Oral Multiple Sclerosis Therapy.....II-119
1$100
   Abbott Laboratories (USA).....II-120
Amgen Inc. (USA).....II-120
1$100
   Bayer Schering Pharma AG (Germany).....II-1211$100
   Biogen Idec Inc. (USA).....II-1221$100
   Bristol-Myers Squibb Company (USA).....II-123
Elan Corporation plc (Ireland).....II-123
1$100
   Eli Lilly and Company (USA).....II-1241$100
   F. Hoffmann-La Roche AG (Switzerland).....II-125
Chugai Pharmaceutical Co., Ltd. (Japan).....II-125
1$100
   Genentech, Inc. (USA).....II-1261$100
   GlaxoSmithKline Plc (UK).....II-1271$100
   Johnson & Johnson, Inc. (USA).....II-128
Merck & Co., Inc. (US).....II-128
1$100
   Merck Serono SA (Switzerland).....II-1291$100
   Novartis AG (Switzerland).....II-130
Sanofi-aventis SA (France).....II-130
1$100
   Shire Plc (Ireland).....II-131
Teva Pharmaceuticals Industries Limited (Israel).....II-131
1$100
   UCB S.A. (Belgium).....II-1321$100
   Table 5: World Recent Past, Current & Future Analysis for Autoimmune Disease Therapeutics by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-1331$350
   Table 6: World Historic Review for Autoimmune Disease Therapeutics by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1341$350
   Table 7: World 15-year Perspective for Autoimmune Disease Therapeutics by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1351$350
   Table 8: World Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics (Biologics) by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-1361$350
   Table 9: World Historic Review for Rheumatoid Arthritis Therapeutics (Biologics) by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1371$350
   Table 10: World 15-year Perspective for Rheumatoid Arthritis Therapeutics (Biologics) by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1381$350
   Table 11: World Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-1391$350
   Table 12: World Historic Review for Multiple Sclerosis Therapeutics by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1401$350
   Table 13: World 15-year Perspective for Multiple Sclerosis Therapeutics by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1411$350
   Table 14: World Recent Past, Current & Future Analysis for Psoriasis Therapeutics by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-1421$350
   Table 15: World Historic Review for Psoriasis Therapeutics by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1431$350
   Table 16: World 15-year Perspective for Psoriasis Therapeutics by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1441$350
   Table 17: World Recent Past, Current & Future Analysis for Crohn’s Disease Therapeutics (Biologicals) by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-1451$350
   Table 18: World Historic Review for Crohn’s Disease Therapeutics (Biologicals) by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1461$350
   Table 19: World 15-year Perspective for Crohn’s Disease Therapeutics (Biologicals) by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1471$350
   Table 20: World Recent Past, Current & Future Analysis for Other Autoimmune Disease Therapeutics by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-1481$350
   Table 21: World Historic Review for Other Autoimmune Disease Therapeutics by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1491$350
   Table 22: World 15-year Perspective for Other Autoimmune Disease Therapeutics by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1501$350
   A. Market Analysis.....II-151
Current and Future Analysis.....II-151
Autoimmune Diseases Fact Sheet.....II-151
1$100
   Table 23: Prevalence of Key Autoimmune Diseases in the US (in Millions) (includes corresponding Graph/Chart).....II-152
Market Trends.....II-152
Biologic Drugs Lead the Fray.....II-152
Biologics To Add Further Impetus to the Market.....II-152
1$350
   Rheumatoid Arthritis Drugs Lead the Market.....II-153
Enbrel and Humira Continue to Gain Share in the Anti-TNF Market.....II-153
Increased Incidence and Rise in Drug Prices to Drive Growth in MS Market.....II-153
1$100
   Table 24: Leading Multiple Sclerosis Drugs in the US (2008): Percentage Share Breakdown of New Prescriptions Written for Avonex, Copaxone, Rebif, Betaseron, and Tysabri (includes corresponding Graph/Chart).....II-154
Incidence of Type 1 Diabetes Mellitus Endemic in White Youth.....II-154
Lialda’s Share Gaining Momentum in Ulcerative Colitis Drugs Market.....II-154
1$350
   Key Ulcerative Colitis Drugs Market in the US (2006).....II-155
Product Launches/Approvals.....II-155
6$600
   Strategic Corporate Developments.....II-16130$595
   Key Players.....II-1917$395
   B. Market Analytics.....II-198
Table 25: US Recent Past, Current & Future Analysis for Autoimmune Disease Therapeutics by Disease Segment – Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune Diseases Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-198
1$350
   Table 26: US Historic Review for Autoimmune Disease Therapeutics by Disease Segment – Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune Diseases Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1991$350
   Table 27: US 15-Year Perspective for Autoimmune Disease Therapeutics by Disease Segment – Percentage Breakdown of Dollar Sales for Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune Diseases for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-2001$350
   A. Market Analysis.....II-201
Current and Future Analysis.....II-201
Japanese Patients Exhibit Unique Efficacy & Safety Effects.....II-201
Product Launches/Approvals.....II-201
1$100
   Strategic Corporate Developments.....II-2021$100
   Key Players.....II-2031$100
   B. Market Analytics.....II-204
Table 28: Japanese Recent Past, Current & Future Analysis for Autoimmune Disease Therapeutics by Disease Segment – Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune Diseases Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-204
1$350
   Table 29: Japanese Historic Review for Autoimmune Disease Therapeutics by Disease Segment – Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune Diseases Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-2051$350
   Table 30: Japanese 15-Year Perspective for Autoimmune Disease Therapeutics by Disease Segment – Percentage Breakdown of Dollar Sales for Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune Diseases for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-2061$350
   A. Market Analysis.....II-207
Current and Future Analysis.....II-207
Europe – A Burgeoning Market for Autoimmune Disease Therapeutics.....II-207
Increasing Awareness to Drive Market Growth.....II-207
Low Penetration to Fuel Growth in European MS DMDs Market.....II-207
1$100
   Table 31: Prevalence of Key Autoimmune Diseases in Europe in Millions (includes corresponding Graph/Chart).....II-208
Lower Treatment Rate Bodes Huge Potential for the UK MS Drug Market.....II-208
Drugs Hindering Disease Progression to Gain Prominence.....II-208
Rising Demand for Rheumatoid Arthritis Drugs in Russia.....II-208
1$350
   Product Launches/Approvals.....II-2093$150
   Strategic Corporate Developments.....II-21210$295
   Key Players.....II-2226$295
   B. Market Analytics.....II-228
Table 32: European Recent Past, Current & Future Analysis for Autoimmune Disease Therapeutics by Disease Segment – Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune Diseases Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-228
1$350
   Table 33: European Historic Review for Autoimmune Disease Therapeutics by Disease Segment – Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune Diseases Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-2291$350
   Table 34: European 15-Year Perspective for Autoimmune Disease Therapeutics by Disease Segment – Percentage Breakdown of Dollar Sales for Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics), and Other Autoimmune Diseases for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-2301$350
   A. Market Analysis.....II-231
Current and Future Analysis.....II-231
Canada.....II-231
Canada – Highest Prevalence Rates for Multiple Sclerosis.....II-231
Sales of Biologics on the Rise in Canadian Rheumatoid Arthritis Drugs
  Market.....II-231
1$100
   Asia-Pacific.....II-232
Autoimmune Diseases Market in Asia-Pacific – An Overview.....II-232
Incidence of Multiple Sclerosis in India on the Rise.....II-232
1$100
   Overview of Rheumatoid Arthritis in Australia.....II-233
Table 35: Percentage Breakdown of Prevalence of Rheumatoid Arthritis in Australia by Age Group (includes corresponding Graph/Chart).....II-233
1$350
   Table 36: Percentage Breakdown of Prevalence of Rheumatoid Arthritis in Australia by Sex (includes corresponding Graph/Chart).....II-234
Overview of Irritable Bowel Diseases in Australia.....II-234
1$350
   Product Launches/Approvals.....II-2352$100
   Strategic Corporate Developments.....II-2374$200
   Key Player.....II-2412$150
   B. Market Analytics.....II-243
Table 37: Rest of World Recent Past, Current & Future Analysis for Autoimmune Disease Therapeutics by Disease Segment – Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune Diseases Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-243
1$350
   Table 38: Rest of world Historic Review for Autoimmune Disease Therapeutics by Disease Segment – Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune Diseases Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-2441$350
   Table 39: Rest of World 15-Year Perspective for Autoimmune Disease Therapeutics by Disease Segment – Percentage Breakdown of Dollar Sales for Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune Diseases for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-2451$350
  
Total Companies Profiled: 138 (including Divisions/Subsidiaries - 155)

Region/Country Players

The United States 83 Canada 6 Japan 7 Europe 43 France 2 Germany 8 The United Kingdom 10 Italy 1 Rest of Europe 22 Asia-Pacific (Excluding Japan) 10 Middle East 6
Click here to request a full table of contents and more details on this project.